Wu Y, Lin L, Liu X
Dis Markers. 2020; 2020:7291586.
PMID: 32587640
PMC: 7303743.
DOI: 10.1155/2020/7291586.
Zhang Z, Chen Y, Ma M, Hao J, Ding R, Han L
Oncotarget. 2017; 8(56):96453-96459.
PMID: 29221220
PMC: 5707114.
DOI: 10.18632/oncotarget.19089.
Kumar R, Yu F, Zhen Y, Li B, Wang J, Yang Y
Onco Targets Ther. 2017; 10:3453-3465.
PMID: 28761354
PMC: 5516878.
DOI: 10.2147/OTT.S130131.
Taylor S, Huang Y, Mallett G, Stathopoulou C, Felizardo T, Sun M
J Exp Med. 2017; 214(6):1663-1678.
PMID: 28490441
PMC: 5461001.
DOI: 10.1084/jem.20161653.
Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J
Cancer Immunol Immunother. 2017; 66(9):1175-1187.
PMID: 28451792
PMC: 5579171.
DOI: 10.1007/s00262-017-2005-z.
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.
Guo L, Zhang H, Chen B
J Cancer. 2017; 8(3):410-416.
PMID: 28261342
PMC: 5332892.
DOI: 10.7150/jca.17144.
Potential role of immunotherapy in advanced non-small-cell lung cancer.
de Mello R, Veloso A, Esrom Catarina P, Nadine S, Antoniou G
Onco Targets Ther. 2016; 10:21-30.
PMID: 28031719
PMC: 5179204.
DOI: 10.2147/OTT.S90459.
Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
Su S, Hu Y, Ouyang W, Ma Z, Li Q, Li H
BMC Cancer. 2016; 16(1):908.
PMID: 27871270
PMC: 5117544.
DOI: 10.1186/s12885-016-2952-3.
Immunotherapy for lung cancer.
Gonzalez-Cao M
Transl Lung Cancer Res. 2016; 4(6):675-7.
PMID: 26798576
PMC: 4700218.
DOI: 10.3978/j.issn.2218-6751.2015.12.07.
Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.
Au J, Yeung B, Wientjes M, Lu Z, Wientjes M
Adv Drug Deliv Rev. 2015; 97:280-301.
PMID: 26686425
PMC: 4829347.
DOI: 10.1016/j.addr.2015.12.002.
